Literature DB >> 22921864

Molecular mechanisms mediating metastasis of hypoxic breast cancer cells.

Gregg L Semenza1.   

Abstract

Breast cancers contain regions of intratumoral hypoxia in which reduced O(2) availability activates the hypoxia-inducible factors HIF-1 and HIF-2, which increase the transcription of genes encoding proteins that are required for many important steps in cancer progression. Recently, HIFs have been shown to play critical roles in the metastasis of breast cancer to the lungs through the transcriptional activation of genes encoding angiopoietin-like 4 and L1 cell adhesion molecule, which promote the extravasation of circulating cancer cells from the lung vasculature, and the lysyl oxidase family members LOX, LOXL2, and LOXL4, which promote invasion and metastatic niche formation. Digoxin, a drug that inhibits HIF-1 activity, blocks primary tumor growth, vascularization, invasion, and metastasis in ex vivo and in vivo assays.
Copyright © 2012. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22921864      PMCID: PMC3449282          DOI: 10.1016/j.molmed.2012.08.001

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  57 in total

1.  HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression.

Authors:  E Laughner; P Taghavi; K Chiles; P C Mahon; G L Semenza
Journal:  Mol Cell Biol       Date:  2001-06       Impact factor: 4.272

2.  Tumor hypoxia and malignant progression.

Authors:  Peter Vaupel; Arnulf Mayer; Michael Höckel
Journal:  Methods Enzymol       Date:  2004       Impact factor: 1.600

3.  MDA-MB-435 and M14 cell lines: identical but not M14 melanoma?

Authors:  Ann F Chambers
Journal:  Cancer Res       Date:  2009-06-23       Impact factor: 12.701

4.  Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch.

Authors:  David Lando; Daniel J Peet; Dean A Whelan; Jeffrey J Gorman; Murray L Whitelaw
Journal:  Science       Date:  2002-02-01       Impact factor: 47.728

5.  Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.

Authors:  Reinhard Bos; Petra van der Groep; Astrid E Greijer; Avi Shvarts; Sybren Meijer; Herbert M Pinedo; Gregg L Semenza; Paul J van Diest; Elsken van der Wall
Journal:  Cancer       Date:  2003-03-15       Impact factor: 6.860

6.  Metastasis: quantitative analysis of distribution and fate of tumor emboli labeled with 125 I-5-iodo-2'-deoxyuridine.

Authors:  I J Fidler
Journal:  J Natl Cancer Inst       Date:  1970-10       Impact factor: 13.506

7.  Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation.

Authors:  P Jaakkola; D R Mole; Y M Tian; M I Wilson; J Gielbert; S J Gaskell; A von Kriegsheim; H F Hebestreit; M Mukherji; C J Schofield; P H Maxwell; C W Pugh; P J Ratcliffe
Journal:  Science       Date:  2001-04-05       Impact factor: 47.728

8.  HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation.

Authors:  F Yu; S B White; Q Zhao; F S Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-14       Impact factor: 11.205

9.  Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis.

Authors:  R Bos; H Zhong; C F Hanrahan; E C Mommers; G L Semenza; H M Pinedo; M D Abeloff; J W Simons; P J van Diest; E van der Wall
Journal:  J Natl Cancer Inst       Date:  2001-02-21       Impact factor: 13.506

10.  Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer.

Authors:  Monika Schindl; Sebastian F Schoppmann; Hellmut Samonigg; Hubert Hausmaninger; Werner Kwasny; Michael Gnant; Raimund Jakesz; Ernst Kubista; Peter Birner; Georg Oberhuber
Journal:  Clin Cancer Res       Date:  2002-06       Impact factor: 12.531

View more
  93 in total

Review 1.  HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations.

Authors:  Gregg L Semenza
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

2.  Targeting the Tumor Core: Hypoxia-Responsive Nanoparticles for the Delivery of Chemotherapy to Pancreatic Tumors.

Authors:  Matthew I Confeld; Babak Mamnoon; Li Feng; Heather Jensen-Smith; Priyanka Ray; James Froberg; Jiha Kim; Michael A Hollingsworth; Mohiuddin Quadir; Yongki Choi; Sanku Mallik
Journal:  Mol Pharm       Date:  2020-07-22       Impact factor: 4.939

3.  Microvesicles derived from human bone marrow mesenchymal stem cells promote U2OS cell growth under hypoxia: the role of PI3K/AKT and HIF-1α.

Authors:  Shanshan Lin; Bo Zhu; Guozhi Huang; Qing Zeng; Chuhuai Wang
Journal:  Hum Cell       Date:  2018-11-30       Impact factor: 4.174

Review 4.  Metabolic implication of tumor:stroma crosstalk in breast cancer.

Authors:  Andrea Morandi; Paola Chiarugi
Journal:  J Mol Med (Berl)       Date:  2014-01-24       Impact factor: 4.599

Review 5.  Metabolic control of the Treg/Th17 axis.

Authors:  Joseph Barbi; Drew Pardoll; Fan Pan
Journal:  Immunol Rev       Date:  2013-03       Impact factor: 12.988

Review 6.  Extracellular Hsp90 (eHsp90) as the actual target in clinical trials: intentionally or unintentionally.

Authors:  Wei Li; Fred Tsen; Divya Sahu; Ayesha Bhatia; Mei Chen; Gabriele Multhoff; David T Woodley
Journal:  Int Rev Cell Mol Biol       Date:  2013       Impact factor: 6.813

Review 7.  Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response.

Authors:  S R McKeown
Journal:  Br J Radiol       Date:  2014-03       Impact factor: 3.039

Review 8.  Reengineering the Tumor Microenvironment to Alleviate Hypoxia and Overcome Cancer Heterogeneity.

Authors:  John D Martin; Dai Fukumura; Dan G Duda; Yves Boucher; Rakesh K Jain
Journal:  Cold Spring Harb Perspect Med       Date:  2016-12-01       Impact factor: 6.915

Review 9.  HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond.

Authors:  Patrick H Maxwell; Kai-Uwe Eckardt
Journal:  Nat Rev Nephrol       Date:  2015-12-14       Impact factor: 28.314

10.  Concurrent targeting of eicosanoid receptor 1/eicosanoid receptor 4 receptors and COX-2 induces synergistic apoptosis in Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus associated non-Hodgkin lymphoma cell lines.

Authors:  Arun George Paul; Bala Chandran; Neelam Sharma-Walia
Journal:  Transl Res       Date:  2013-03-20       Impact factor: 7.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.